Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roman A Blaheta

Showing results (31-40 of 127) with videos related to

Pageof 13
Sort By:
Journal of Cellular and Molecular Medicine|December 3, 2014
Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenibEva Juengel, Dana Kim, Jasmina Makarević, et al.
International Journal of Molecular Medicine|December 29, 2015
Amygdalin inhibits the growth of renal cell carcinoma cells in vitroEva Juengel, Anita Thomas, Jochen Rutz, et al.
Anti-Cancer Drugs|August 9, 2011
HDAC inhibition delays cell cycle progression of human bladder cancer cells in vitroStefan Vallo, Wang Xi, Lukasz Hudak, et al.
Plos One|January 4, 2014
I publish in I edit?--Do editorial board members of urologic journals preferentially publish their own scientific work?Jens Mani, Jasmina Makarević, Eva Juengel, et al.
Molecular Medicine Reports|April 12, 2011
CXC chemokine mRNA expression as a potential diagnostic tool in prostate cancerSteffen A Wedel, Ivaylo N Raditchev, Jon Jones, et al.
Experimental Cell Research|August 21, 2007
CXCR4 chemokine receptor engagement modifies integrin dependent adhesion of renal carcinoma cellsJon Jones, Dana Marian, Eva Weich, et al.
Cancer Letters|July 21, 2018
Relevance of the natural HDAC inhibitor sulforaphane as a chemopreventive agent in urologic tumorsEva Juengel, Holger H H Erb, Axel Haferkamp, et al.
BMC Cancer|May 29, 2009
Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cellsEva Juengel, Johanna Engler, Iyad Natsheh, et al.
Journal of Cellular and Molecular Medicine|September 1, 2007
Transient down-regulation of beta1 integrin subtypes on kidney carcinoma cells is induced by mechanical contact with endothelial cell membranesJon Jones, Stefan Berkhoff, Eva Weich, et al.
Neoplasia (New York, N.Y.)|May 28, 2014
Resistance to the mTOR inhibitor temsirolimus alters adhesion and migration behavior of renal cell carcinoma cells through an integrin α5- and integrin β3-dependent mechanismEva Juengel, Jasmina Makarević, Michael Reiter, et al.
Pageof 13

Showing results (31-40 of 127) with videos related to

Sort By:
Pageof 13
Journal of Cellular and Molecular Medicine|December 3, 2014
Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenibEva Juengel, Dana Kim, Jasmina Makarević, et al.
International Journal of Molecular Medicine|December 29, 2015
Amygdalin inhibits the growth of renal cell carcinoma cells in vitroEva Juengel, Anita Thomas, Jochen Rutz, et al.
Anti-Cancer Drugs|August 9, 2011
HDAC inhibition delays cell cycle progression of human bladder cancer cells in vitroStefan Vallo, Wang Xi, Lukasz Hudak, et al.
Plos One|January 4, 2014
I publish in I edit?--Do editorial board members of urologic journals preferentially publish their own scientific work?Jens Mani, Jasmina Makarević, Eva Juengel, et al.
Molecular Medicine Reports|April 12, 2011
CXC chemokine mRNA expression as a potential diagnostic tool in prostate cancerSteffen A Wedel, Ivaylo N Raditchev, Jon Jones, et al.
Experimental Cell Research|August 21, 2007
CXCR4 chemokine receptor engagement modifies integrin dependent adhesion of renal carcinoma cellsJon Jones, Dana Marian, Eva Weich, et al.
Cancer Letters|July 21, 2018
Relevance of the natural HDAC inhibitor sulforaphane as a chemopreventive agent in urologic tumorsEva Juengel, Holger H H Erb, Axel Haferkamp, et al.
BMC Cancer|May 29, 2009
Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cellsEva Juengel, Johanna Engler, Iyad Natsheh, et al.
Journal of Cellular and Molecular Medicine|September 1, 2007
Transient down-regulation of beta1 integrin subtypes on kidney carcinoma cells is induced by mechanical contact with endothelial cell membranesJon Jones, Stefan Berkhoff, Eva Weich, et al.
Neoplasia (New York, N.Y.)|May 28, 2014
Resistance to the mTOR inhibitor temsirolimus alters adhesion and migration behavior of renal cell carcinoma cells through an integrin α5- and integrin β3-dependent mechanismEva Juengel, Jasmina Makarević, Michael Reiter, et al.
Pageof 13